ResearchAndMarkets.com added separate reports forecasting sales and market size through 2034 for selinexor, pelabresib and REBLOZYL across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. Selinexor is marketed as XPOVIO for multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma, while its potential myelofibrosis use is supported by Phase III SENTRY data showing a statistically significant spleen-volume-reduction result but not a statistically significant total-symptom-score result. Pelabresib remains investigational; in Phase III MANIFEST-2, 65.9% of patients receiving pelabresib plus ruxolitinib achieved at least a 35% spleen-volume reduction at Week 24, versus 35.2% with placebo plus ruxolitinib, while the overall total symptom score endpoint was not statistically significant. REBLOZYL is approved for beta-thalassemia and myelodysplastic syndromes, with potential opportunities in myelofibrosis and alpha-thalassemia; in COMMANDS, 58.5% of patients achieved at least 12 weeks of red blood cell transfusion independence with a hemoglobin increase of at least 1.5 g/dL, compared with 31.2% for epoetin alfa. The reports assess clinical development, regulatory milestones, pricing, reimbursement, patents, generic-entry risks, competition and commercial scenarios.